SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors (Cell Reports)

Ahmed et al. identify molecular determinants of tumor response to combined targeting with SHP2 and ERK signaling inhibitors. This strategy was effective in triple-negative breast cancer and molecularly defined subsets of RAS and BRAF-mutant tumor models. The results provide a roadmap for the translation of this strategy to the clinic.